C

    Citius Pharmaceuticals Inc (CTXR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.58
    -0.02 (-3.64%)

    Market Cap: $16.53M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(16/33)
    Avg Surprise
    -72.85%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.05
    Range$-1.05 - $-1.05
    1 analysts
    Revenue Consensus
    $1M
    Range$1M - $1M
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.38
    Range$-0.38 - $-0.38
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-0.38
    Revenue Consensus
    $4M
    Range$4M - $4M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.38---
    Sep 26EST
    		-$-1.05---
    Jun 26
    		$-0.34$-0.36+5.56%Beat+57.5%
    Mar 26
    		$-0.95$-0.32-196.88%Miss+25.2%
    Dec 25
    		$-0.38$-0.30-26.67%Miss+70.8%
    Sep 25
    		$-0.11N/A+54.17%Beat+98.1%
    Jun 25
    		$-0.80$-0.21-280.95%Miss+46.7%
    Mar 25
    		$-1.27$0.11-1254.55%Miss-1.6%
    Dec 24
    		$-1.30$-1.25-4.00%Miss-2066.7%
    Sep 24
    		$-5.80$-1.50-286.67%Miss-231.4%
    Jun 24
    		$-1.50$-1.12-33.93%Miss+0.0%
    Mar 24
    		$-1.25$-1.50+16.67%Beat+28.6%
    Dec 23
    		$-0.06N/A-146.15%Miss-200.0%
    Sep 23
    		$-1.75$-1.50-16.67%Miss-40.0%
    Jun 23
    		$-1.50$-1.75+14.29%Beat+0.0%
    Mar 23
    		$-1.75$-1.25-40.00%Miss-40.0%
    Dec 22
    		$-0.02N/A+66.67%Beat+98.7%
    Sep 22
    		$-1.25$-1.50+16.67%Beat-6150.0%
    Jun 22
    		$-1.50$-1.50+0.00%Beat-20.0%
    Mar 22
    		$-1.25$-1.75+28.57%Beat-25.0%
    Dec 21
    		$-1.50$-1.50+0.00%Beat-900.0%
    Sep 21
    		$-0.02$-0.04+50.00%Beat+98.9%
    Jun 21
    		$-1.25$-1.00-25.00%Miss+54.5%
    Mar 21
    		$-1.00N/A+55.56%Beat+69.2%
    Dec 20
    		$-0.15$0.16-193.75%Miss+96.0%
    Sep 20
    		$-1.75$-2.50+30.00%Beat-993.8%
    Jun 20
    		$-2.75$-2.75+0.00%Beat+45.0%
    Mar 20
    		$-3.25$-2.75-18.18%Miss+35.0%
    Dec 19
    		$-3.75$-3.50-7.14%Miss+31.8%
    Sep 19
    		$-0.16$-0.14-14.29%Miss+0.0%
    Jun 19
    		$-5.00$-1.50-233.33%Miss-5.3%
    Mar 19
    		$-5.00$-5.00+0.00%Beat-1036.4%
    Dec 18
    		$-5.50$-5.25-4.76%Miss-1347.4%
    Sep 18
    		$-0.16$-0.16+0.00%Beat+62.8%
    Jun 18
    		$-4.75$-8.00+40.63%Beat-869.4%
    Mar 18
    		$-0.44N/AN/ABeat+20.0%
    Dec 17
    		$-0.38N/AN/ABeat+96.6%
    Sep 17
    		$-0.43N/AN/ABeat+96.8%
    Jun 17
    		$-0.49N/AN/ABeat-
    Mar 17
    		$-0.55N/AN/ABeat-
    Dec 16
    		$-11.09N/AN/ABeat-
    Sep 16
    		$-13.28N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.33EV/EBITDA-2.74x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-670.00%
    ROE-81.10%ROIC-84.31%
    Financial Health
    Debt/Equity0.10xInterest Coverage-133.14x
    Current Ratio0.84xQuick Ratio0.40x
    Trading Statistics
    Beta0.99Avg Volume974.58K
    52-Week High$2.1952-Week Low$0.47

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.60
    SMA 20$0.65
    SMA 50$0.59
    SMA 200$0.77
    EMA 10$0.61
    EMA 20$0.61
    EMA 50$0.61
    EMA 200$0.78

    MACD

    Line: -0.00Signal: 0.01Hist: -0.01

    ADX

    ADX: 26.0+DI: 28.6-DI: 18.5

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down4.0
    PSAR$0.78

    Bollinger Bands

    Upper Band$0.79
    Lower Band$0.50
    %B Position4386%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    46.9

    Momentum Oscillators

    Stoch %K22.9
    Stoch %D22.6
    Williams %R-86.9
    ROC (10d)3.2%
    Momentum0.02
    CCI (20d)-77.1
    MFI (14d)60.5

    Volatility Measures

    ATR (14d)$0.07(11.3%)
    StdDev (20d)0.07
    Hist Vol167.9%(High)

    Volume Flow

    VWAP$0.58
    OBV91.4M
    AD Line-63.8M
    CMF (20d)0.034

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio0.3x(Low)
    VWMA (20d)$0.67

    Pivot Points

    R3$0.66
    R2$0.65
    R1$0.62
    Pivot Point$0.61
    S1$0.58
    S2$0.57
    S3$0.54

    Advanced Oscillators

    TSI-0.81
    Ultimate Osc38.1
    KST61.43

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.49M$1.67M$3.94M$0$0$0$0$155,926$0$0$0$0
    Cost of Revenue$491,843$328,878$789,208$62,038$0$0$0$155,926$0$0$0$49,969
    Gross Profit$1.00M$1.34M$3.15M$-62,038$0$0$0$-53,685$0$0$0$-49,969
    Operating Expenses$12.73M$33.53M$12.17M$8.44M$8.79M$11.26M$10.04M$11.05M$10.63M$10.97M$9.34M$10.12M
    R&D$2.77M$3.35M$2.17M$1.64M$1.62M$3.77M$2.13M$2.91M$2.76M$3.61M$2.62M$2.88M
    SG&A$6.15M$26.39M$5.72M$3.91M$4.45M$4.79M$5.39M$5.49M$4.81M$4.29M$3.66M$4.17M
    Operating Income$-11,732,074$-32,194,786$-9,019,208$-8,437,309$-8,788,007$-11,260,678$-10,039,614$-11,050,478$-10,634,179$-10,970,201$-9,340,823$-10,124,723
    Interest Income$116,691$3.89M$45,097$53,423$20,637$13,413$22,608$117,314$204,843$182,205$253,638$324,813
    Interest Expense$231,732$33,031$155,538$42,097$172,262$0$0$0$0$0$0$0
    Income Before Tax$-12,026,607$-28,340,956$-9,129,649$-8,479,406$-8,939,632$-11,247,265$-10,017,006$-10,933,164$-10,429,336$-8,400,154$-9,087,185$-9,799,910
    Income Tax Expense$-107,347$-231,210$264,240$264,240$264,240$264,240$264,240$144,000$144,000$144,000$144,000$144,000
    Net Income$-11,919,260$-28,109,746$-9,393,889$-8,743,646$-9,203,872$-11,511,505$-10,281,246$-11,077,164$-10,573,336$-8,544,154$-9,231,185$-9,943,910
    EBITDA$-9,970,283$-30,433,815$-8,462,253$-8,375,271$-8,746,640$-11,204,668$-9,984,779$-10,996,793$-10,581,331$-8,530,289$-9,289,815$-10,074,754
    EBIT$-11,911,566$-32,194,786$-9,019,208$-8,437,309$-8,788,007$-11,260,678$-10,039,614$-11,050,478$-10,634,179$-8,582,359$-9,340,823$-10,124,723
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CTXR

    News

    Citius Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

    Citius Pharmaceuticals (CTXR) has received an extension from Nasdaq until February 8, 2027, to regain compliance with the $1.00 minimum bid price rule. To meet this requirement, the stock must close at or above $1.00 for at least ten consecutive business days. Failure to comply will result in delisting, though the company retains the right to appeal.

    TradingView•8/21/26•
    Bearish

    H.C. Wainwright reiterates Citius Pharmaceuticals stock rating at buy By Investing.com

    H.C. Wainwright has reiterated a Buy rating for Citius Pharmaceuticals (NASDAQ:CTXR) with a $4.00 price target, noting that the stock is currently trading significantly below InvestingPro’s Fair Value, suggesting it may be undervalued. Despite profitability challenges, the firm projects future revenue growth for LYMPHIR, with institutional vial orders increasing and July orders reaching a new high. H.C. Wainwright maintains its 12-month price target based on these projections.

    Investing.com Canada•8/19/26•
    Bullish

    Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

    Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong revenue growth for LYMPHIR, generating $7.1 million with a 77% gross margin in the first nine months of fiscal 2026, driven by increased institutional orders. Despite a current cash position of $17.0 million and an underlying manageable burn rate after excluding a non-recurring charge, the company's financial stability hinges on accelerated institutional uptake to close the gap between gross margin and operating losses.

    The Clinical Trial Vanguard•8/16/26•
    Somewhat-Bullish

    Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress

    Citius Pharmaceuticals reported strong Q3 2026 financial results, including $7.1 million in commercial sales revenue for the first nine months of the fiscal year and $17 million in cash reserves. The company highlighted significant progress with its lead product, LYMPHIR, noting an 86% objective response rate in clinical trials and a 78% increase in institutional orders, alongside an expansion of its commercial and medical affairs teams to enhance market penetration and patient services.

    Intellectia AI•8/14/26•
    Neutral

    Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

    CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of 4.99% and 9.99%. Heights Capital Management acts as the investment manager for CVI Investments, holding shared voting and dispositive power over these shares.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About CTXR

    Does CTXR pay dividends?
    Citius Pharmaceuticals Inc (CTXR) does not currently pay a regular dividend.
    What is CTXR's market cap?
    Citius Pharmaceuticals Inc (CTXR) has a market capitalization of $16.53M with a current stock price of $0.58.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In